Novo Nordisk Received an Upgrade from UBS for Its Ozempic …
2 days ago · Despite Trump's tariff threat to Denmark and recent underwhelming trial data for Novo Nordisk's experimental obesity drug Carigsema, an upgrade came to Novo Nordisk from UBS from Neutral to a Buy ...
Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy at UBS Group
20 hours ago · Shares of Novo Nordisk A/S stock opened at $85.63 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month ...
NVO Stock Up 3% as UBS Upgrades Company Rating From …
1 day ago · Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from “Neutral” to “Buy.” Novo Nordisk markets its semaglutide ...
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker
2 days ago · Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock ...
Novo Nordisk upgraded to Buy from Neutral at UBS, as …
3 days ago · UBS analyst upgraded Novo Nordisk to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” to continue to benefit from the high demand for GLP-1 ...
Novo Nordisk A/S (NYSE:NVO) Upgraded to "Buy" at UBS Group
3 days ago · Novo Nordisk A/S Stock Up 2.7 %. Shares of NVO stock traded up $2.29 on Wednesday, hitting $85.63. 9,192,861 shares of the stock were exchanged, compared to its average volume of 7,559,210. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $384.27 billion, a P/E ratio of 27.71, a price-to-earnings-growth ...
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off ...
2 days ago · Shares in Novo slumped in December after trials of Novo's latest candidate to succeed Wegovy, CagriSema, showed it helped patients reduce their weight by 22.7% -- below Novo's expected target of 25%.
UBS raises Novo Nordisk stock rating to buy, cuts price target
3 days ago · On Wednesday, UBS analyst Jo Walton upgraded Novo Nordisk (NYSE: NVO) stock from a Sell to a Buy rating, though the price target was adjusted to DKK750.00 from the previous DKK1,100.00. The change ...
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off ...
2 days ago · Investing.com - Novo Nordisk (CSE: NOVOb) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near-term demand for new weight-loss drugs, according to analysts at UBS. In a note to clients raising their rating of the Danish group's stock to "buy" from "neutral", the analysts led by Jo Walton argued that sales of so ...
UBS Upgrades Novo Nordisk A (NVO) - Nasdaq
Dec 23, 2024 · Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. As of December 23, 2024, the average one-year price target for Novo Nordisk A is ...